Last reviewed · How we verify
The INSPIRE-Lung Study
NA trial testing LungTalk in Lung Cancer in 512 participants. Completed in 30 July 2024.
| Lead sponsor | Hackensack Meridian Health |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 512 |
| Start date | 2 August 2023 |
| Primary completion | 30 July 2024 |
| Estimated completion | 30 July 2024 |
| Sites | 1 location across United States |
Hackensack Meridian Health — full company profile →
Adults 50 to 80, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Leveraging a well-established, social media-based platform (Facebook) to target screening-eligible individuals in the community. This will be measured by the total number of people who saw the FBTA at least once.
| Group | Value | 95% CI |
|---|---|---|
| Unique Facebook Users Who Saw the Add | 1048191 |
Leveraging a well-established, social media-based platform (Facebook) to target screening-eligible individuals in the community. This will be measured by the total number of clicks on the link within the FBTA that led to the REDCap survey platform of the study.
| Group | Value | 95% CI |
|---|---|---|
| Unique Facebook Users Who Clicked on the Link | 24816 |
Leveraging a well-established, social media-based platform (Facebook) to target screening-eligible individuals in the community. This will be measured by the total number of times the FBTA was on screen (may include multiple views of the ad by the same person/people).
| Group | Value | 95% CI |
|---|---|---|
| Ad on Screen | 3109482 |
The assessment plan is intended to compare the effectiveness of a tailored (LungTalk) versus non-tailored health communication and decision support tool delivered online to improve total knowledge about lung screening. The total Knowledge of Lung Cancer Screening will be assessed with a 9-item multidimensional scale ranging from 0 to 9 with 0 being "No Knowledge" and 9 being "Complete knowledge".
| Group | Value | 95% CI |
|---|---|---|
| Tailored Health Communication Intervention (LungTalk) | 4 | 0 – 9 |
| Non-tailored Intervention | 4 | 0 – 9 |
The assessment plan is intended to compare the effectiveness of a tailored (LungTalk) versus non-tailored health communication and decision support tool delivered online to improve total knowledge about lung screening. The total Knowledge of Lung Cancer Screening will be assessed with a 9-item multidimensional scale ranging from 0 to 9 with 0 being "No Knowledge" and 9 being "Complete knowledge".
| Group | Value | 95% CI |
|---|---|---|
| Tailored Health Communication Intervention (LungTalk) | 6 | 1 – 9 |
| Non-tailored Intervention | 6 | 1 – 9 |
The assessment plan is intended to compare the effectiveness of a tailored (LungTalk) versus non-tailored health communication and decision support tool delivered online to improve Perceived Risk. Perceived Risk of Lung Cancer is a 3-item scale with Likert-type responses. The range of scores is 3 to 12 (higher perceived risk of lung cancer).
| Group | Value | 95% CI |
|---|---|---|
| Tailored Health Communication Intervention (LungTalk) | 6 | 3 – 12 |
| Non-tailored Intervention | 6 | 3 – 12 |
The assessment plan is intended to compare the effectiveness of a tailored (LungTalk) versus non-tailored health communication and decision support tool delivered online to improve Perceived Risk. Perceived Risk of Lung Cancer is a 3-item scale with Likert-type responses. The range of scores is 3 to 12 (higher perceived risk of lung cancer).
| Group | Value | 95% CI |
|---|---|---|
| Tailored Health Communication Intervention (LungTalk) | 7 | 3 – 12 |
| Non-tailored Intervention | 7 | 3 – 12 |
The assessment plan is intended to compare the effectiveness of a tailored (LungTalk) versus non-tailored health communication and decision support tool delivered online to improve Perceived Benefits. Perceived Benefits of Lung Cancer Screening is a 6-item scale with responses ranging from 1=strongly disagree to 4=strongly agree. The range of scores is 6 to 24 (higher perceived benefits).
| Group | Value | 95% CI |
|---|---|---|
| Tailored Health Communication Intervention (LungTalk) | 20 | 6 – 24 |
| Non-tailored Intervention | 19 | 6 – 24 |
The assessment plan is intended to compare the effectiveness of a tailored (LungTalk) versus non-tailored health communication and decision support tool delivered online to improve Perceived Benefits. Perceived Benefits of Lung Cancer Screening is a 6-item scale with responses ranging from 1=strongly disagree to 4=strongly agree. The range of scores is 6 to 24 (higher perceived benefits).
| Group | Value | 95% CI |
|---|---|---|
| Tailored Health Communication Intervention (LungTalk) | 20.5 | 7 – 24 |
| Non-tailored Intervention | 21 | 6 – 24 |
The assessment plan is intended to compare the effectiveness of a tailored (LungTalk) versus non-tailored health communication and decision support tool delivered online to improve Perceived Barriers. Perceived Barriers to Lung Cancer Screening. This scale has 17 items with four-point Likert responses where 1=strongly disagree and 4=strongly agree. The range of scores is 17 to 68 (higher perceived barriers).
| Group | Value | 95% CI |
|---|---|---|
| Tailored Health Communication Intervention (LungTalk) | 33 | 17 – 66 |
| Non-tailored Intervention | 31 | 17 – 68 |
The assessment plan is intended to compare the effectiveness of a tailored (LungTalk) versus non-tailored health communication and decision support tool delivered online to improve Perceived Barriers. Perceived Barriers to Lung Cancer Screening. This scale has 17 items with four-point Likert responses where 1=strongly disagree and 4=strongly agree. The range of scores is 17 to 68 (higher perceived barriers).
| Group | Value | 95% CI |
|---|---|---|
| Tailored Health Communication Intervention (LungTalk) | 25 | 17 – 58 |
| Non-tailored Intervention | 25 | 17 – 54 |
The assessment plan is intended to compare the effectiveness of a tailored (LungTalk) versus non-tailored health communication and decision support tool delivered online to improve Self-Efficacy. Self-Efficacy for Lung Cancer Screening will be assessed using a scale with nine items with a four-point Likert response option to assess individual beliefs about ability to arrange and complete a low-dose computed tomography (LDCT) to screen for lung cancer. The range of scores is 9 to 36 (higher levels of self-efficacy).
| Group | Value | 95% CI |
|---|---|---|
| Tailored Health Communication Intervention (LungTalk) | 31 | 15 – 36 |
| Non-tailored Intervention | 31 | 15 – 36 |
LungTalk and leveraging Facebook-targeted Advertisement (FBTA) addresses the call to develop and test multi-level, cancer communication interventions using innovative methods and designs. The study's long term goal is to increase lung cancer screening uptake among appropriate, high-risk individuals nationwide.
4 peer-reviewed publications reference this trial (live from Europe PMC):
Verify or expand the search:
Trials testing the same drug.
Currently open trials in the same condition.
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05824273.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing